[Appropriate pharmacological therapy after surgical or percutaneous myocardial revascularization].
Faggiano
Pompilio
P
U.O. di Cardiologia, Spedali Civili, e Cattedra di Cardiologia, Università degli Studi, Brescia. faggiano@numerica.it
De Feo
Stefania
S
Frattini
Silvia
S
Tramarin
Roberto
R
Dei Cas
Livio
L
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D015906:Angioplasty, Balloon, Coronary; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000628:therapy; D009204:Myocardial Revascularization / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors